Alignment Healthcare has achieved a decisive turnaround, with revenue growth accelerating to 31.6% year-over-year in 2026Q2 and the combined ratio improving to 96.8%, marking the first sustained quarterly profitability. The company's scale-driven expense disci...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 30, 2026 | $0.17+31.8% vs $0.13 | $1.3B+2.0% vs $1.3B |
Q2 2026 Apr 30, 2026 | $0.05+400.0% vs $0.01 | $1.2B+1.4% vs $1.2B |
Q1 2026 Feb 26, 2026 | -$0.05+66.7% vs -$0.15 | $1.0B+0.9% vs $1.0B |
Q4 2025 Oct 30, 2025 | $0.02+300.0% vs -$0.01 | $994M+1.3% vs $981M |
Alignment Healthcare, Inc. (NASDAQ: ALHC - Get Free Report) shares reached a new 52-week low during trading on Wednesday. The stock traded as low as $9.94 and last traded at $10.37, with a volume of 28545880 shares trading hands. The stock had previously closed at $12.94. More Alignment Healthcare News Here are the key news
Key indicators worsened in 2026, including aging in place challenges, support gaps, and medical debt Key indicators worsened in 2026, including aging in place challenges, support gaps, and medical debt
Expanded provider relationship increases access to Hoag physicians, hospitals and specialty programs beginning Jan. 1, 2027 Expanded provider relationship increases access to Hoag physicians, hospitals and specialty programs beginning Jan. 1, 2027
NEW YORK, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Alignment Healthcare, Inc. (“Alignment Healthcare” or the “Company”) (NASDAQ: ALHC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are an Alignment Healthcare investor and have suffered losses, or if you have information that could assist in the Alignment Healthcare investigation, you may CLICK HERE to contact us.
Benchmark ALHC against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Alignment Healthcare, Inc. (ALHC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $7.86 | $1.62B | -2124.32 | 46.06% | -0.02% | -0.52% | — | |
| $62.07 | $30.66B | -4.56 | 19.44% | -2.63% | -23.94% | — | |
| $189.37 | $9.89B | 21.23 | 11.75% | -0.02% | -0.17% | — | |
| $85.86 | $109.55B | 61.77 | 7.85% | 1.18% | 6.41% | — | |
| $374.80 | $45B | 38.09 | 10.06% | 0.88% | 6.89% | — | |
| $398.56 | $86.44B | 15.87 | 12.62% | 2.47% | 11.2% | — |
Alignment Healthcare, Inc. (ALHC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Alignment Healthcare, Inc. (ALHC) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 30, 2026·SEC
Jun 9, 2026·SEC
May 12, 2026·SEC
Get notified when ALHC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Alignment Healthcare, Inc. (ALHC) stock FAQ — growth, dividends, profitability & financials explained
Alignment Healthcare, Inc. (ALHC) grew revenue by 46.1% over the past year. This is strong growth.
Yes, Alignment Healthcare, Inc. (ALHC) is profitable, generating $40.7M in net income for fiscal year 2025 (-0.0% net margin).
Alignment Healthcare, Inc. (ALHC) has a return on equity (ROE) of -0.5%. Negative ROE indicates the company is unprofitable.
Alignment Healthcare, Inc. (ALHC) has a combined ratio of 99.6%. A ratio below 100% indicates underwriting profitability.
